---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-043670"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2022-04-07T23:59:59+00:00"
generated_at: "2026-06-26T08:47:57.125289+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# VYNE reports positive Phase 1b data for FMX114 in atopic dermatitis; appoints Baker Tilly as auditor after PwC dismissal

## Summary
- FMX114 showed statistically significant reduction in ADSI score at week 2: -81.4% mean reduction vs -54.3% for vehicle (p=0.004).
- Pruritus reduced 96.4% mean from baseline for FMX114 vs 45.8% for vehicle at week 2.
- Phase 2a safety and efficacy results expected in Q2 2022.
- Audit committee dismissed PwC as auditor effective April 6, 2022; appointed Baker Tilly US, LLP as new auditor.
- PwC's 2021 report included going concern explanatory paragraph due to incurred losses and negative cash flows.

## SEC filing metadata
- accession: 0001104659-22-043670
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2022-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 4.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465922043670/0001104659-22-043670-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465922043670/tm228420d7_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-043670
- JSON: https://secwatch.observer/filing/0001104659-22-043670.json
- Plain text: https://secwatch.observer/filing/0001104659-22-043670.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.